The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C02 | Antihypertensives | |
| 3 | C02K | Other antihypertensives | |
| 4 | C02KN | Other antihypertensives | |
| 5 | C02KN01 |
| Active Ingredient | Description | |
|---|---|---|
| Aprocitentan |
Endothelin (ET)-1, via its receptors (ETA and ETB), mediates a variety of effects such as vasoconstriction, fibrosis, cell proliferation, and inflammation and is upregulated in hypertension. Aprocitentan is a dual ERA that inhibits the binding of ET-1 to ETA and ETB receptors and hence the effects mediated by these receptors. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| JERAYGO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| TRYVIO Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
